Routine inflammatory markers are elevated in myelodysplastic syndromes at presentation Inflammatory marker elevation in MDS

Main Article Content

Howard Oster
Ekaterina Sklyar
Noa Golsdshmidt
Moshe Mittelman

Keywords

Myelodysplastic syndromes, Inflammation, C-reactive protein, Erythrocyte sedimentation rate

Abstract

Background: Immune and inflammatory processes have known contributions to the pathogenesis of myelodysplastic syndromes (MDS). The use of inflammatory markers, minimally used in current practice, is examined.


 

Downloads

Download data is not yet available.


Abstract 224
PDF Downloads 369
HTML Downloads 132

References

1 Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391-2405.
2 Cazzola M: Myelodysplastic Syndromes. N Engl J Med 2020;383:1358-1374.
3 Garcia-Manero G: Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. American journal of hematology 2014;89:97-108.
4 Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, Della Porta MG, Fenaux P, Gattermann N, Germing U, Jansen JH, Mittelman M, Mufti G, Platzbecker U, Sanz GF, Selleslag D, Skov-Holm M, Stauder R, Symeonidis A, van de Loosdrecht AA, de Witte T, Cazzola M, European Leukemia N: Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013;122:2943-2964.
5 Mittelman M: The myelodysplastic syndromes--1990. Isr J Med Sci 1990;26:468-478.
6 Sekeres MA, Taylor J: Diagnosis and Treatment of Myelodysplastic Syndromes: A Review. JAMA 2022;328:872-880.
7 Tefferi A, Vardiman JW: Myelodysplastic syndromes. N Engl J Med 2009;361:1872-1885.
8 Kouroukli O, Symeonidis A, Foukas P, Maragkou MK, Kourea EP: Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes. Cancers (Basel) 2022;14.
9 Nielsen AB, Hansen JW, Orskov AD, Dimopoulos K, Salem M, Grigorian M, Bruunsgaard H, Gronbaek K: Inflammatory Cytokine Profiles Do Not Differ Between Patients With Idiopathic Cytopenias of Undetermined Significance and Myelodysplastic Syndromes. Hemasphere 2022;6:e0713.
10 Sallman DA, List A: The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood 2019;133:1039-1048.
11 Winter S, Shoaie S, Kordasti S, Platzbecker U: Integrating the "Immunome" in the Stratification of Myelodysplastic Syndromes and Future Clinical Trial Design. J Clin Oncol 2020;38:1723-1735.
12 Mekinian A, Grignano E, Braun T, Decaux O, Liozon E, Costedoat-Chalumeau N, Kahn JE, Hamidou M, Park S, Puechal X, Toussirot E, Falgarone G, Launay D, Morel N, Trouiller S, Mathian A, Gombert B, Schoindre Y, Lioger B, De Wazieres B, Amoura Z, Buchdaul AL, Georgin-Lavialle S, Dion J, Madaule S, Raffray L, Cathebras P, Piette JC, Rose C, Ziza JM, Lortholary O, Montestruc F, Omouri M, Denis G, Rossignol J, Nimubona S, Ades L, Gardin C, Fenaux P, Fain O: Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford) 2016;55:291-300.
13 Saif MW, Hopkins JL, Gore SD: Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 2002;43:2083-2092.
14 Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A: Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol 2018;14:576-590.
15 Weeks LD, Marinac CR, Redd R, Abel G, Lin A, Agrawal M, Stone RM, Schrag D, Ebert BL: Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2022;139:1246-1250.
16 Miller A, Green M, Robinson D: Simple rule for calculating normal erythrocyte sedimentation rate. Br Med J (Clin Res Ed) 1983;286:266.
17 Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O'Neill LA, Wei S, List AF: The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood 2016;128:2960-2975.
18 Cluzeau T, McGraw KL, Irvine B, Masala E, Ades L, Basiorka AA, Maciejewski J, Auberger P, Wei S, Fenaux P, Santini V, List A: Pro-inflammatory proteins S100A9 and tumor necrosis factor-alpha suppress erythropoietin elaboration in myelodysplastic syndromes. Haematologica 2017;102:2015-2020.
19 Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, Chambert K, Mick E, Neale BM, Fromer M, Purcell SM, Svantesson O, Landen M, Hoglund M, Lehmann S, Gabriel SB, Moran JL, Lander ES, Sullivan PF, Sklar P, Gronberg H, Hultman CM, McCarroll SA: Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014;371:2477-2487.
20 Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC, Mermel CH, Burtt N, Chavez A, Higgins JM, Moltchanov V, Kuo FC, Kluk MJ, Henderson B, Kinnunen L, Koistinen HA, Ladenvall C, Getz G, Correa A, Banahan BF, Gabriel S, Kathiresan S, Stringham HM, McCarthy MI, Boehnke M, Tuomilehto J, Haiman C, Groop L, Atzmon G, Wilson JG, Neuberg D, Altshuler D, Ebert BL: Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014;371:2488-2498.
21 Trowbridge JJ, Starczynowski DT: Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS. The Journal of experimental medicine 2021;218.
22 Conte M, Martucci M, Chiariello A, Franceschi C, Salvioli S: Mitochondria, immunosenescence and inflammaging: a role for mitokines? Semin Immunopathol 2020;42:607-617.
23 Chee L, Ritchie D, Ludford-Menting M, Ripley J, Chung J, Park D, Norton S, Kenealy M, Koldej R: Dysregulation of immune cell and cytokine signalling correlates with clinical outcomes in myelodysplastic syndrome (MDS). Eur J Haematol 2022;108:342-353.
24 Wolach O, Stone R: Autoimmunity and Inflammation in Myelodysplastic Syndromes. Acta Haematol 2016;136:108-117.
25 Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA: Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 2009;100:822-828.
26 Wilson AB, Neogi T, Prout M, Jick S: Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the General Practice Research Database. Cancer Epidemiol 2014;38:544-549.
27 Zhao L-P, Boy M, Azoulay C, Clappier E, Sébert M, Amable L, Klibi J, Benlagha K, Espeli M, Balabanian K, Preudhomme C, Marceau A, Itzykson R, Mékinian A, Fain O, Toubert A, Fenaux P, Dulphy N, Ades L: MDS/CMML with TET2 or IDH mutation Are Associated with Systemic Inflammatory and Autoimmune Diseases (SIAD) and T Cell Dysregulation. Blood 2020;136:31-32.
28 Shi C, Gong S, Niu T, Li T, Wu A, Zheng X, Yang S, Ouyang G, Mu Q: The Prognostic Value of Pretherapy Peripheral Blood Inflammatory Indices in Myelodysplastic Syndromes. Front Oncol 2022;12:877981.
29 Comont T, Treiner E, Vergez F: From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review. Diagnostics (Basel) 2021;11.